Developer docs
API playgroundTry for free, no card

Search company profiles

Ensysce Biosciences

Full company profile

uuid000046t

Namestring
Ensysce Biosciences
Legal namestring
Ensysce Biosciences, Inc.
Websiteurl
ensysce.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Ensysce Biosciences is a clinical-stage biopharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs built on two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). TAAP chemically modifies active pharmaceutical ingredients into inactive prodrugs that only activate upon contact with trypsin in the small intestine, preventing activation via crushing, snorting, or injection. MPAR adds a trypsin inhibitor (nafamostat) that limits drug release when more than prescribed doses are consumed, providing oral overdose protection. The lead product PF614 is a TAAP oxycodone prodrug currently in Phase 3 clinical trials for severe post-surgical pain, with PF614-MPAR combining PF614 with nafamostat for overdose protection. The pipeline extends into TAAP amphetamine prodrugs (PF8001, PF8026) for ADHD and PF9001 for opioid use disorder.

The company pursues FDA approval under the 505(b)(2) NDA pathway with PF614 holding Fast Track designation and PF614-MPAR holding Breakthrough Therapy designation. Ensysce plans future commercialization through traditional pharmaceutical distribution channels (retail and hospital pharmacies) supported by manufacturing partnerships with Purisys (Noramco subsidiary) and Galephar. The company currently has no commercial revenue and funds operations through NIH/NIDA grants (over $34 million cumulatively) and dilutive equity financings. As of early 2026, the Board initiated review of strategic alternatives including potential partnerships, licensing arrangements, or asset sales. Ensysce faces going concern uncertainty and Nasdaq listing qualification challenges due to stockholders' equity deficiency.

Short descriptiontext

Ensysce Biosciences is a clinical-stage biopharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs using proprietary TAAP and MPAR platforms, with lead candidate PF614 in Phase 3 trials for severe pain and no commercial revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
abuse-deterrent opioids, prodrug pharmaceutical development, overdose protection technology, opioid pain therapeutics, clinical-stage biopharmaceutical
Industry1 code
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pain Management Pharmaceuticals
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Once regulatory approval is obtained, Ensysce plans to commercialize its abuse-deterrent opioid products (PF614, PF614-MPAR) through traditional pharmaceutical sales channels. The company is currently in Phase 3 clinical trials with market entry anticipated within 18-24 months of trial initiation.

ensysce.com
2Technology Licensing
TypeLicensing Royalties
Description

Ensysce offers out-licensing opportunities for its TAAP™ and MPAR® technologies to other pharmaceutical companies for product differentiation and market expansion. The company has over 100 issued patents globally to support licensing arrangements.

ensysce.com
3Grant Funding (Non-Dilutive)
TypeManaged Services
Description

The company receives grant funding from NIH and NIDA to support clinical development of PF614-MPAR and other programs. Received $14 million NIH grant and $15 million NIH/NIDA award for opioid use disorder programs.

ensysce.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ensysce Biosciences is a clinical-stage pharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs using two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). Its lead candidate PF614 is in Phase 3 trials for severe and chronic pain, while PF614-MPAR combines the TAAP prodrug with the protease inhibitor nafamostat to deliver the first oral opioid with overdose protection and has received FDA Breakthrough Therapy designation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • PF614 demonstrated bioequivalence to OxyContin 40mg when given as PF614 100mg in healthy subjects
+3 more records
Product overview1 text field

Ensysce Biosciences is developing a portfolio of abuse-deterrent and overdose-protected opioid prodrugs using two proprietary technology platforms: TAAP (Trypsin-Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance). The lead product PF614 (TAAP oxycodone) is in Phase 3 clinical trials for severe pain. PF614-MPAR combines PF614 with nafamostat for overdose protection and has received FDA Breakthrough Therapy designation. The company is also developing PF8001/PF8026 (TAAP amphetamines for ADHD) and PF9001 (for opioid use disorder) using these platforms.

Product and service7 records
1PF614
CategoryPain Management Pharmaceuticals
Description

An oxycodone-based prodrug built on the TAAP™ platform, designed to treat severe and/or chronic pain. It is chemically modified to be inactive until swallowed, when digestive enzymes in the small intestine release oxycodone, providing 12-hour pain relief with abuse-deterrent properties. Received FDA Fast Track designation.

2PF614-MPAR
CategoryPain Management Pharmaceuticals
Description

Combines PF614 with the trypsin inhibitor nafamostat to deliver both abuse resistance and overdose protection; positioned as the first oral overdose-protected opioid. Received FDA Breakthrough Therapy designation.

3PF9001
CategoryOpioid Use Disorder Therapeutics
Description

Lead clinical candidate for the treatment of opioid use disorder, using TAAP™ technology to provide reduced cardiovascular side effects and lower abuse potential.

4PF8001
CategoryADHD Therapeutics
Description

Extended-release prodrug of amphetamine built on the TAAP™ platform, designed to improve safety and reduce abuse potential of ADHD medications.

5PF8026
CategoryADHD Therapeutics
Description

Immediate-release prodrug of amphetamine built on the TAAP™ platform, intended for ADHD treatment with improved safety and reduced abuse potential.

6TAAP™ Technology Platform
CategoryTechnology Licensing Platform
Description

Proprietary prodrug technology platform offered for out-licensing to other pharmaceutical companies. Ensures opioids (or other oral drugs) are only activated when swallowed and contact trypsin in the small intestine, preventing abuse via snorting, injection, or chewing.

7MPAR® Technology Platform
Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-20
Description

Manufacturing partnership supporting FDA-aligned commercial production strategy for PF614. Purisys, a subsidiary of Noramco, is providing manufacturing capabilities to support the company's pathway toward regulatory approval and commercial scale-up.

2Galephar
Strategic tierCoreTypeTechnology or Integration
Description

Manufacturing partner engaged in production activities for PF614 alongside Purisys to ensure adequate commercial supply upon regulatory approval.

za.investing.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers7 records
TypeEmerging player
Description

Nektar is a clinical-stage company exploring novel pain and CNS mechanisms with comparable small-cap, clinical-stage profile to Ensysce. Comparable in scale and capital markets dynamics if not in exact therapeutic focus.

TypeBroad incumbent
Description

Mallinckrodt markets generic and branded opioids including abuse-deterrent oxycodone formulations, and has historically competed in the severe pain category. Represents a broader specialty pharma incumbent with overlapping opioid portfolio.

TypeDirect peer
Description

Collegium markets Xtampza ER (abuse-deterrent oxycodone ER) and Nucynta (tapentadol), the closest direct competitors to PF614 in the abuse-deterrent opioid pain space. Both target the same severe/chronic pain prescriber base and pharmacy channels.

TypeDirect peer
Description

Trevena developed and commercialized OLINVYK (oliceridine), a branded opioid analgesic for moderate-to-severe acute pain in hospital settings. Comparable clinical-stage-to-commercial journey with a differentiated opioid mechanism.

TypeDirect peer
Description

BDSI commercialized Belbuca, a buprenorphine-based pain product with abuse-deterrent properties, and was ultimately acquired by Collegium. Directly comparable as a small-cap abuse-deterrent opioid specialist targeting similar pain specialists.

TypeBroad incumbent
Description

Vertex is advancing suzetrigine (NaV1.8 inhibitor) and other non-opioid pain candidates, representing the most prominent emerging competitive threat to opioid-based pain therapies. While not directly competing on mechanism, both target the same severe pain prescribers and patient pool.

TypeBroad incumbent
Description

Purdue's OxyContin established the abuse-deterrent reformulated opioid category that PF614 seeks to disrupt. Although now in bankruptcy restructuring, Purdue remains a reference point for branded abuse-deterrent opioid commercialization.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ensysce Biosciences

Pain Management Pharmaceuticalsensysce.com

Ensysce Biosciences is a clinical-stage biopharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs using proprietary TAAP and MPAR platforms, with lead candidate PF614 in Phase 3 trials for severe pain and no commercial revenue.

What Ensysce Biosciences does

Ensysce Biosciences is a clinical-stage biopharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs built on two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). TAAP chemically modifies active pharmaceutical ingredients into inactive prodrugs that only activate upon contact with trypsin in the small intestine, preventing activation via crushing, snorting, or injection. MPAR adds a trypsin inhibitor (nafamostat) that limits drug release when more than prescribed doses are consumed, providing oral overdose protection. The lead product PF614 is a TAAP oxycodone prodrug currently in Phase 3 clinical trials for severe post-surgical pain, with PF614-MPAR combining PF614 with nafamostat for overdose protection. The pipeline extends into TAAP amphetamine prodrugs (PF8001, PF8026) for ADHD and PF9001 for opioid use disorder.

The company pursues FDA approval under the 505(b)(2) NDA pathway with PF614 holding Fast Track designation and PF614-MPAR holding Breakthrough Therapy designation. Ensysce plans future commercialization through traditional pharmaceutical distribution channels (retail and hospital pharmacies) supported by manufacturing partnerships with Purisys (Noramco subsidiary) and Galephar. The company currently has no commercial revenue and funds operations through NIH/NIDA grants (over $34 million cumulatively) and dilutive equity financings. As of early 2026, the Board initiated review of strategic alternatives including potential partnerships, licensing arrangements, or asset sales. Ensysce faces going concern uncertainty and Nasdaq listing qualification challenges due to stockholders' equity deficiency.

Ensysce Biosciences firmographics

Firmographics
Name
Ensysce Biosciences
Legal name
Ensysce Biosciences, Inc.
Website
https://ensysce.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Ensysce Biosciences is a clinical-stage biopharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs using proprietary TAAP and MPAR platforms, with lead candidate PF614 in Phase 3 trials for severe pain and no commercial revenue.
Ownership category
akta.pro rank

Ensysce Biosciences industry classification

Industry
Product category
Pain Management Pharmaceuticals
NAICS
Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Abuse-deterrent opioids
  • Prodrug pharmaceutical development
  • Overdose protection technology
  • Opioid pain therapeutics
  • Clinical-stage biopharmaceutical

Where Ensysce Biosciences is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ensysce Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical Product Sales: Once regulatory approval is obtained, Ensysce plans to commercialize its abuse-deterrent opioid products (PF614, PF614-MPAR) through traditional pharmaceutical sales channels. The company is currently in Phase 3 clinical trials with market entry anticipated within 18-24 months of trial initiation.
  2. Technology Licensing: Ensysce offers out-licensing opportunities for its TAAP™ and MPAR® technologies to other pharmaceutical companies for product differentiation and market expansion. The company has over 100 issued patents globally to support licensing arrangements.
  3. Grant Funding (Non-Dilutive): The company receives grant funding from NIH and NIDA to support clinical development of PF614-MPAR and other programs. Received $14 million NIH grant and $15 million NIH/NIDA award for opioid use disorder programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels10 records

Ensysce Biosciences product offering

Product offering

Core offering

Ensysce Biosciences is a clinical-stage pharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs using two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). Its lead candidate PF614 is in Phase 3 trials for severe and chronic pain, while PF614-MPAR combines the TAAP prodrug with the protease inhibitor nafamostat to deliver the first oral opioid with overdose protection and has received FDA Breakthrough Therapy designation.

Product overview

Ensysce Biosciences is developing a portfolio of abuse-deterrent and overdose-protected opioid prodrugs using two proprietary technology platforms: TAAP (Trypsin-Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance). The lead product PF614 (TAAP oxycodone) is in Phase 3 clinical trials for severe pain. PF614-MPAR combines PF614 with nafamostat for overdose protection and has received FDA Breakthrough Therapy designation. The company is also developing PF8001/PF8026 (TAAP amphetamines for ADHD) and PF9001 (for opioid use disorder) using these platforms.

Differentiator

Problem solved

Functional benefit

Products and services

  • PF614 An oxycodone-based prodrug built on the TAAP™ platform, designed to treat severe and/or chronic pain. It is chemically modified to be inactive until swallowed, when digestive enzymes in the small intestine release oxycodone, providing 12-hour pain relief with abuse-deterrent properties. Received FDA Fast Track designation.
  • PF614-MPAR Combines PF614 with the trypsin inhibitor nafamostat to deliver both abuse resistance and overdose protection; positioned as the first oral overdose-protected opioid. Received FDA Breakthrough Therapy designation.
  • PF9001 Lead clinical candidate for the treatment of opioid use disorder, using TAAP™ technology to provide reduced cardiovascular side effects and lower abuse potential.
  • PF8001 Extended-release prodrug of amphetamine built on the TAAP™ platform, designed to improve safety and reduce abuse potential of ADHD medications.
  • PF8026 Immediate-release prodrug of amphetamine built on the TAAP™ platform, intended for ADHD treatment with improved safety and reduced abuse potential.
  • TAAP™ Technology Platform Proprietary prodrug technology platform offered for out-licensing to other pharmaceutical companies. Ensures opioids (or other oral drugs) are only activated when swallowed and contact trypsin in the small intestine, preventing abuse via snorting, injection, or chewing.
  • MPAR® Technology Platform

Quantifiable outcome

  • PF614 demonstrated bioequivalence to OxyContin 40mg when given as PF614 100mg in healthy subjects
  • +3 more outcomes

Companies that use Ensysce Biosciences

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Ensysce Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ensysce Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Purisys, LLC (subsidiary of Noramco, LLC)coreTechnology or Integration · 20 November 2025Manufacturing partnership supporting FDA-aligned commercial production strategy for PF614. Purisys, a subsidiary of Noramco, is providing manufacturing capabilities to support the company's pathway toward regulatory approval and commercial scale-up.
  • GalepharcoreTechnology or IntegrationManufacturing partner engaged in production activities for PF614 alongside Purisys to ensure adequate commercial supply upon regulatory approval.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Ensysce Biosciences competitors and assessment

Company assessment

Emerging players

  • Nektar Therapeutics: Nektar is a clinical-stage company exploring novel pain and CNS mechanisms with comparable small-cap, clinical-stage profile to Ensysce. Comparable in scale and capital markets dynamics if not in exact therapeutic focus.

Broad incumbents

  • Mallinckrodt Pharmaceuticals: Mallinckrodt markets generic and branded opioids including abuse-deterrent oxycodone formulations, and has historically competed in the severe pain category. Represents a broader specialty pharma incumbent with overlapping opioid portfolio.
  • Vertex Pharmaceuticals: Vertex is advancing suzetrigine (NaV1.8 inhibitor) and other non-opioid pain candidates, representing the most prominent emerging competitive threat to opioid-based pain therapies. While not directly competing on mechanism, both target the same severe pain prescribers and patient pool.
  • Purdue Pharma: Purdue's OxyContin established the abuse-deterrent reformulated opioid category that PF614 seeks to disrupt. Although now in bankruptcy restructuring, Purdue remains a reference point for branded abuse-deterrent opioid commercialization.

Direct peers

  • Collegium Pharmaceutical: Collegium markets Xtampza ER (abuse-deterrent oxycodone ER) and Nucynta (tapentadol), the closest direct competitors to PF614 in the abuse-deterrent opioid pain space. Both target the same severe/chronic pain prescriber base and pharmacy channels.
  • Trevena: Trevena developed and commercialized OLINVYK (oliceridine), a branded opioid analgesic for moderate-to-severe acute pain in hospital settings. Comparable clinical-stage-to-commercial journey with a differentiated opioid mechanism.
  • BioDelivery Sciences International: BDSI commercialized Belbuca, a buprenorphine-based pain product with abuse-deterrent properties, and was ultimately acquired by Collegium. Directly comparable as a small-cap abuse-deterrent opioid specialist targeting similar pain specialists.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Ensysce Biosciences social profiles

Digital presence

Ensysce Biosciences compliance and trust

Trust signal

Compliance2 records

Ensysce Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ensysce Biosciences leadership team

Management profile

Number of profiles

Profiles13 records

Ensysce Biosciences funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ensysce Biosciences M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ensysce Biosciences

What does Ensysce Biosciences do?

Ensysce Biosciences is a clinical-stage pharmaceutical company developing abuse-deterrent and overdose-protected opioid prodrugs using two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). Its lead candidate PF614 is in Phase 3 trials for severe and chronic pain, while PF614-MPAR combines the TAAP prodrug with the protease inhibitor nafamostat to deliver the first oral opioid with overdose protection and has received FDA Breakthrough Therapy designation.

Is Ensysce Biosciences a public or private company?

Ensysce Biosciences is a public company. It is classified as public and is currently operating.

When was Ensysce Biosciences founded?

Ensysce Biosciences was founded in 2008. It employs 11 to 50 people.

Where is Ensysce Biosciences based?

Ensysce Biosciences is headquartered in La Jolla, United States, in the North America region.

How does Ensysce Biosciences make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are technology Licensing and grant Funding (Non-Dilutive).

Who are Ensysce Biosciences's main competitors?

Nektar Therapeutics is listed as an emerging player. Broad incumbents are Mallinckrodt Pharmaceuticals, Vertex Pharmaceuticals and Purdue Pharma. Direct peers are Collegium Pharmaceutical, Trevena and BioDelivery Sciences International.

Does Ensysce Biosciences have an API?

No public API is recorded for Ensysce Biosciences.

What industry is Ensysce Biosciences in?

Ensysce Biosciences's product category is Pain Management Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsAnalyzing Iterum Therapeutics (NASDAQ:ITRM) and Ensysce Biosciences (NASDAQ:ENSC)Ensysce Biosciences outperforms Iterum Therapeutics on revenue, earnings, and analyst ratings, with a consensus target price of $2.00 implying 378% upside. Iterum Therapeutics beats Ensysce on 8 of 14 factors, but Ensysce is more affordable and less volatile.American Banking and Market NewsEnsysce Biosciences (NASDAQ:ENSC) Coverage Initiated by Analysts at UBS GroupUBS Group initiated coverage on Ensysce Biosciences with a buy rating and a $2.00 target price. The stock opened at $0.39, and the company reported a loss of $0.20 per share for the quarter, meeting consensus estimates. Analysts have a consensus rating of Hold with an average price target of $2.00.American Banking and Market NewsHead-To-Head Contrast: Merck KGaA (OTCMKTS:MKKGY) and Ensysce Biosciences (NASDAQ:ENSC)Ensysce Biosciences and Merck KGaA are compared on institutional ownership, analyst ratings, valuation, and profitability. Ensysce has a consensus target price of $2.00 with 356.62% upside, while Merck has higher revenue and earnings. Ensysce is trading at a lower price-to-earnings ratio.Ticker ReportReviewing Ensysce Biosciences (NASDAQ:ENSC) and Axsome Therapeutics (NASDAQ:AXSM)A comparison of Ensysce Biosciences and Axsome Therapeutics evaluates profitability, analyst ratings, and valuation. Axsome Therapeutics beats Ensysce on 10 of 15 factors, with a consensus price target of $274.68 versus $2.00 for Ensysce. Axsome is also more affordable and less volatile.American Banking and Market NewsCantor Fitzgerald Begins Coverage on Ensysce Biosciences (NASDAQ:ENSC)Cantor Fitzgerald began coverage on Ensysce Biosciences with an overweight rating and a $2.00 price target, implying 284.62% upside. The stock opened at $0.52, and the company reported a loss of $0.20 per share for the quarter, meeting consensus estimates.Ticker ReportEnsysce Biosciences (NASDAQ:ENSC) versus Hypermarcas (OTCMKTS:HYPMY) Head to Head ComparisonHypermarcas outperforms Ensysce Biosciences on 10 of 13 comparison factors, including revenue and profitability. Hypermarcas has $1.38 billion in revenue versus Ensysce's $5.07 million, and a positive net margin of 19.77% versus Ensysce's -280.53%. Ensysce trades at a lower price-to-earnings ratio, making it the more affordable stock.Stock TitanEnsysce Biosciences submits CY200 protocol to UK MHRAEnsysce Biosciences submitted a Phase 2a protocol for CY200 to the UK MHRA, testing analgesic efficacy in adults with CRPS Type 1 versus placebo. The study, CYBIO_001, is a multicenter, randomized, double-blind, placebo-controlled trial. The company expects the MHRA review to mark a pivotal step toward initiating the study.NewswireEnsysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRAEnsysce Biosciences submitted a Phase 2a protocol for CY200 to the UK MHRA for a CRPS Type 1 study. The study will evaluate analgesic efficacy versus placebo in adult participants. The submission marks a step toward initiating the trial.Stock TitanEnsysce Biosciences Joins FDA Psychedelic Drug HearingEnsysce Biosciences hosted a CRPS symposium at PainWeek 2026 and participated in an FDA hearing on psychedelic drug regulation. Dr. Richard Langford discussed access, data collection, and training, while CEO Lynn Kirkpatrick expressed eagerness to advance its Phase 2 trial.NewswireEnsysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug RegulationEnsysce Biosciences hosted a CRPS symposium at PainWeek 2026 and submitted comments to an FDA hearing on psychedelic drug regulation. The company's CEO said the hearing provided public input on access, training, and safety, and the firm is eager to advance its Phase 2 clinical trial.